For laboratory research purposes only. Not for human consumption.
French researchers sourcing peptide compounds for in-vitro and preclinical studies are operating in a market that changed materially over the past year. When Peptide Sciences, one of the most-cited US benchmark suppliers, closed in March 2026, the research community lost a common reference point, and demand moved toward EU-based alternatives that ship without customs delays. This guide covers what matters in that sourcing decision for France: the legal framework, COA standards, logistics, and the criteria that separate genuine research-grade suppliers from the rest.
Is It Legal to Buy Research Peptides in France?
Synthetic peptides sold as research chemicals occupy a defined but qualified space in French law, governed primarily by the Code de la santé publique (CSP).
The medicinal-product definition (Art. L.5111-1 CSP). A substance is a medicinal product (médicament) when it is presented as having properties for treating or preventing disease in humans or animals, or when it is administered to restore, correct, or modify physiological functions. A peptide sold exclusively for in-vitro research, labelled “not for human consumption” and carrying no therapeutic claims, generally falls outside that definition. Classification ultimately turns on presentation, composition, and intended use, so the label alone is not an automatic exemption. Medicines and their advertising are overseen by the ANSM (Agence nationale de sécurité du médicament et des produits de santé), which since February 2022 is also the competent authority for classifying controlled and poisonous substances.
Controlled and poisonous substances (Art. L.5132-6 CSP; arrêté du 22 février 1990). France classifies substances as stupéfiants (narcotics) or as substances vénéneuses on Lists I and II. Standard research peptides such as BPC-157, TB-500, GHK-Cu, Epitalon, Selank, Ipamorelin, and most growth hormone secretagogues do not appear on the stupéfiants list or on Lists I/II as of mid-2026. The ANSM updates these lists periodically, so the current status of any novel compound should be verified before ordering.
Two areas carry elevated risk:
GLP-1 class compounds. Semaglutide, tirzepatide, and liraglutide are authorised medicinal products in France and carry elevated regulatory and import scrutiny. Any framing that presents them as therapeutic alternatives to prescription medicines brings them within the médicament definition and the CSP’s medicines-advertising rules, which the ANSM actively enforces. Framing must stay strictly scientific, and researchers should confirm import and handling requirements through their own institution.
Novel compounds. Because the stupéfiants and substances-vénéneuses lists are revised by ANSM decision (the arrêté du 22 février 1990 is amended regularly), researchers should confirm the current classification of any new or analogue compound before ordering.
In practice: French customs (la Douane) generally treats small-quantity research-chemical shipments from within the EU as internal-market movements not subject to import duties or routine inspection. Restricted, mislabelled, or unlawful goods can still be stopped, and orders from outside the EU may be examined and held.
Why EU-Domestic Shipping Matters for French Researchers
France is part of the EU single market and customs union. Suppliers with EU-based warehouses ship peptide orders without the customs delay, documentation burden, or seizure risk that affect shipments arriving from outside the EU. Typical delivery windows from EU warehouses to France:
- Western/Central EU (Romania, Slovakia, Czech Republic): 2–4 business days
- Northern EU (Baltic states): 3–5 business days
- UK-based suppliers: subject to EU import controls post-Brexit; 5–10+ days with variable customs outcomes
For time-sensitive research protocols or compounds that benefit from a short transit, EU-domestic shipping is strongly preferred.
How to Evaluate a Research Peptide Supplier: The COA Standard
The Certificate of Analysis (COA) is the central quality document in research peptide procurement. Its evidentiary value depends entirely on who produced it and how.
The minimum acceptable COA
An acceptable third-party COA for research-grade peptides must include:
- HPLC purity (%): High-Performance Liquid Chromatography with the chromatogram included. Purity should be 98% or higher for research-grade material; 99%+ is achievable and increasingly common among quality suppliers.
- Identity confirmation via LC-MS (Liquid Chromatography-Mass Spectrometry): the observed molecular mass must match the theoretical mass of the named peptide within standard instrument tolerance.
- Lot/batch number matching exactly what is printed on the vial. A COA from a different batch is not a COA for what was received.
- Testing laboratory name, address, and date. Independent labs issue reports on letterhead with contact information. Requests to “contact us for the COA” without a document are a red flag.
- No commercial relationship to the supply chain. The lab must not be owned by, operated by, or co-located with the manufacturer or vendor.
Janoshik Analytical: the EU research peptide reference lab
Janoshik Analytical (Czech Republic) has become the most widely used third-party testing laboratory for research peptides in the European market. Their standard report includes HPLC purity, LC-MS identity confirmation, and amino acid composition where applicable. Reports are issued with a unique report number that can be referenced in procurement documentation.
Extended COA parameters
Some EU suppliers now provide expanded COA packages: endotoxin testing (LAL assay), bioburden (microbial limit testing), heavy-metal screening (ICP-MS), and residual-solvent testing. These parameters matter for cell-culture and small-animal research where contamination artefacts could confound results. If your protocol is sensitivity-limited, request these extended parameters before ordering.
Sourcing Criteria Checklist for French Research Institutions
For researchers at French institutions (CNRS, INSERM, Institut Pasteur, CEA) and universities (Sorbonne Université, Université Paris-Saclay, Aix-Marseille) ordering peptides for non-clinical studies, a standardised supplier-evaluation process reduces both quality risk and administrative overhead:
- COA on product page: independent third-party, correct lot number, HPLC + LC-MS minimum
- EU warehouse: confirmed EU-domestic shipping origin
- Delivery timeline documented: a stated SLA for France specifically, not a generic “EU” figure
- Packaging standard: lyophilised vials in sealed glass, shipped with temperature-appropriate packaging
- Reconstitution documentation, covering bacteriostatic water compatibility, storage temperature (typically −20°C long-term), and solubility notes (aqueous vs organic solvent)
- Legal compliance statement: “for research use only, not for human consumption” on product page and packaging
- Invoice/documentation: commercial invoice for institutional procurement records, VAT-compliant billing
What French Researchers Are Ordering in 2026
Research peptide classes commonly available to and studied by researchers sourcing from France in 2026 include:
Healing and tissue-biology research: BPC-157, TB-500 (Thymosin Beta-4), and their combination. Both are stable compounds with well-characterised HPLC profiles, which keeps COA verification straightforward, and the published preclinical literature is extensive.
Metabolic and receptor-biology research: GLP-1 class compounds (semaglutide, tirzepatide, retatrutide) for receptor pharmacology, islet-cell biology, and adipocyte studies. Note: these require strict research-only framing in all procurement and lab documentation.
Longevity and telomere-biology research: Epitalon (tetrapeptide), GHK-Cu (copper peptide), MOTS-c (mitochondrial-derived peptide). Interest in this cluster has grown following several high-profile publications.
Nootropic and CNS research: Selank, Semax, Dihexa. These neuropeptides have drawn more academic attention as source data from Eastern European research institutions becomes more accessible.
Growth-hormone-axis research: Ipamorelin, CJC-1295, Sermorelin, Hexarelin. Used in pituitary-axis studies and GH-pulse characterisation experiments.
Storage and Handling for Research-Grade Peptides
Proper storage preserves peptide integrity and analytical validity. Standard protocols for lyophilised (freeze-dried) research peptides:
- Long-term storage: −20°C in the original sealed vial, protected from moisture and light
- Working aliquot (post-reconstitution): 4°C refrigerated, typically stable 2–4 weeks depending on the peptide
- Reconstitution vehicle: bacteriostatic water is standard for most peptides; 0.1% acetic acid is used for GH-releasing peptides (GHRP class) with poor aqueous solubility. Low-concentration dimethyl sulfoxide (DMSO) is used for select hydrophobic peptides, so confirm with the supplier’s reconstitution guide.
- Cycle count: minimise freeze-thaw cycles. Single-use aliquots are recommended for sensitive assays.
All storage notes above describe laboratory handling protocols for research compounds. They do not constitute instructions for human use.
Key Questions to Ask Any Supplier Before Ordering
- Which independent laboratory performed the COA, and what was the lot number tested?
- Can you provide the full COA document, rather than only the purity figure, before I place an order?
- Where is your EU warehouse located, and what is the expected delivery time to [French city or postal code]?
- Do you ship with cold-chain packaging for GLP-1 class peptides?
- What is your re-test policy if a received vial shows evidence of degradation?
- Is your packaging labelled for research use only, with no human-use language?
Summary
French researchers have access to a well-developed EU market for research-grade peptides. The legal picture is set by the Code de la santé publique: the médicament definition, the substances-vénéneuses Lists I/II, and the stupéfiants list, all overseen by the ANSM. In practice the differentiators are COA quality (independent third-party, lot-matched, HPLC+MS minimum), EU-domestic shipping logistics, and strict research-only framing. Suppliers with transparent, publicly posted COAs and EU-based inventory are the appropriate starting point for institutional and academic procurement decisions.
CertaPeptides ships from within the EU to France, posts full Janoshik COA documents on every product page, and labels all compounds for research use only. No human-use claims are made.
This article is for research information purposes only. All compounds referenced are supplied exclusively as research chemicals for laboratory use, not as medicinal products, and are not intended for human or animal use. Some compounds named (for example semaglutide and tirzepatide) are active substances in separately authorised medicines; CertaPeptides supplies only research-grade chemicals and makes no therapeutic claims.